Immunitybio Inc (IBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -863,187 | -632,797 | -351,472 | -289,514 | -222,240 |
| Depreciation Amortization | 8,787 | 2,854 | 15,525 | 11,660 | 7,709 |
| Accounts receivable | -10,901 | -700 | -40,211 | -29,656 | -19,766 |
| Accounts payable and accrued liabilities | 3,654 | 3,901 | -190 | -1,169 | 223 |
| Other Working Capital | -913 | -500 | -54,329 | -39,921 | -27,589 |
| Other Operating Activity | 720,707 | 551,883 | 125,741 | 114,042 | 96,012 |
| Operating Cash Flow | $-141,853 | $-75,359 | $-304,936 | $-234,558 | $-165,651 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -303,309 | -139,093 | -241,373 | -195,747 | -15,161 |
| PPE Investments | -5,292 | -1,776 | -3,846 | -2,943 | -2,202 |
| Sale Of Investment | 179,516 | 119,230 | 95,824 | 5,350 | 5,350 |
| Other Investing Activity | -10,034 | -10,011 | -406 | -34 | 0 |
| Investing Cash Flow | $-139,119 | $-31,650 | $-149,801 | $-193,374 | $-12,013 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | 61 | 2,884 | N/A | N/A |
| Debt Issued | 61 | N/A | N/A | N/A | N/A |
| Debt Repayment | -1,779 | -881 | -1,160 | -16 | -4 |
| Common Stock Issued | 202,454 | 156,740 | 400,782 | 347,038 | 173,356 |
| Other Financing Activity | 67,633 | 68,006 | -2,265 | -1,675 | -1,524 |
| Financing Cash Flow | $268,369 | $223,926 | $400,241 | $345,347 | $171,828 |
| Exchange Rate Effect | 119 | 122 | 15 | 10 | 66 |
| Beginning Cash Position | 89,431 | 89,431 | 143,912 | 143,912 | 143,912 |
| End Cash Position | 76,947 | 206,470 | 89,431 | 61,337 | 138,142 |
| Net Cash Flow | $-12,484 | $117,039 | $-54,481 | $-82,575 | $-5,770 |
| Free Cash Flow | |||||
| Operating Cash Flow | -141,853 | -75,359 | -304,936 | -234,558 | -165,651 |
| Capital Expenditure | -5,292 | -1,776 | -3,846 | -2,943 | -2,202 |
| Free Cash Flow | -147,145 | -77,135 | -308,782 | -237,501 | -167,853 |